Form 4: Praxis Precision Medicines CFO Timothy Kelly Reports Stock Transactions

Praxis Precision Medicines' Chief Financial Officer, Timothy Kelly, reported the acquisition of restricted stock units and stock options, as well as the disposal of shares to cover tax obligations.

Summary

• Timothy Kelly, the Chief Financial Officer of Praxis Precision Medicines, reported several transactions involving the company's stock.
• On January 10, 2025, Mr. Kelly was granted 12,500 restricted stock units (RSUs) and 25,000 stock options.
• The RSUs vest in equal annual installments over four years, starting January 10, 2026.
• The stock options vest with 25% on January 10, 2026, and the remaining 75% in 36 equal monthly installments thereafter.
• On January 12, 2025, 676 shares were withheld by the company to cover tax obligations related to the vesting of previously reported RSUs at a price of $63.15 per share.
• Following these transactions, Mr. Kelly directly owns 24,030 shares of Praxis Precision Medicines.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and insider trading reporting, which is generally neutral to positive. The grants are positive for the executive, but the tax withholding is a neutral event.

Positives

• The grant of restricted stock units and stock options to the CFO aligns his interests with the company's long-term performance.
• The vesting schedule of the stock options encourages continued service and commitment from the CFO.

Negatives

• The disposal of 676 shares to cover tax obligations reduces the CFO's direct shareholding.

Risks

• The value of the stock options is dependent on the future performance of the company's stock price.
• The vesting of the restricted stock units and stock options is contingent on the CFO's continued employment with the company.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives engage in transactions involving company stock. It provides transparency into insider trading activities.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common forms of executive compensation in the biotechnology industry, used to align management's interests with shareholders.
• The vesting schedules described are typical for such grants, encouraging long-term commitment from executives.
• Companies like Biogen, Vertex Pharmaceuticals, and Regeneron also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
• The vesting of stock options and restricted stock units incentivizes the CFO to work towards the company's long-term success.

Key Dates

Keywords

stock options, restricted stock units, insider trading, executive compensation, Praxis Precision Medicines, equity, CFO, Timothy Kelly